LATEST NEWS
Long-term follow up data confirms the benefits of perioperative pembrolizumab in early-stage NSCLC
In the KEYNOTE-671, improvements in event-free survival and overall survival were observed after four years of follow up
Tiragolumab plus atezolizumab failed to improve overall survival in advanced non-squamous NSCLC
The reduced efficacy compared to the first-line standard of care led to the termination of the SKYSCRAPER-06 study
An oncolytic adenovirus shows promise in inducing immune response in prostate cancer
Early-phase data suggest that intratumour injections of ORCA-010 may convert cold tumours into immunogenic ones
Sacituzumab govitecan failed to improve overall survival in pre-treated urothelial carcinoma
Despite being active in this disease setting, the antibody-drug conjugate was associated to high rates of neutropenic complications
New data show promise in using liquid biopsies to tailor immunotherapy
Studies explore the prognostic and predictive values of circulating DNA tumour fraction and single-cell RNA sequencing of peripheral blood mononuclear cells
Studies shed new light on the role of the gut microbiome in immunotherapy toxicity
Results underline the need to further characterise dysbiosis, and to develop diagnostic and actionable tools for mainstream integration
COLUMNS
Redispensing cancer medicines means caring for the environment
Some initiatives show that collection and distribution of unused medicines can help tackle drug waste, with a potential impact on emissions associated to oncology therapies
The expanding toolbox for immuno-oncology
Novel treatment approaches show encouraging early results in solid tumours, but ways to boost precision immunotherapy are needed
Off-label use of cancer medicines: an option not without challenges
Together with an off-trial use and off-track access to oncology therapies, a consolidated trend is reported in clinical practice despite the uncertainties on efficacy and safety
OPINIONS
ctDNA and beyond to serve immunotherapy
Umberto Malapelle
Neoadjuvant immunotherapy sets a new standard in stage III melanoma
Christian Blank
Preventing the rise in obesity-related cancers in Asia
Elick Narayan
Translating cancer genome insights into practical clinical tools
Elli Papaemmanuil
Innovation is leading to a comprehensive ‘map’ of tumours
Joakim Lundeberg
OPINIONS
ctDNA and beyond to serve immunotherapy
Umberto Malapelle
Neoadjuvant immunotherapy sets a new standard in stage III melanoma
Christian Blank
Preventing the rise in obesity-related cancers in Asia
Elick Narayan
Translating cancer genome insights into practical clinical tools
Elli Papaemmanuil
Innovation is leading to a comprehensive ‘map’ of tumours
Joakim Lundeberg